Literature DB >> 25334035

Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study.

N Xiang1, M James, S Walters, A Bamford, C Foster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25334035     DOI： 10.1111/hiv.12180

Source DB:  PubMed          Journal:  HIV Med        ISSN： 1464-2662            Impact factor:   3.180


× No keyword cloud information.
  8 in total

1.  Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.

Authors:  A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch
Journal:  HIV Med       Date:  2015-02-03       Impact factor: 3.180

2.  Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.

Authors:  Ann J Melvin; Grace Montepiedra; Lisa Aaron; William A Meyer; Hans M Spiegel; William Borkowsky; Mark J Abzug; Brookie M Best; Marilyn J Crain; Peggy R Borum; Bobbie Graham; Patricia Anthony; Katherine Shin; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2017-01       Impact factor: 2.129

3.  Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.

Authors:  Daisuke Mizushima; Nguyen Thi Hoai Dung; Nguyen Thi Dung; Shoko Matsumoto; Junko Tanuma; Hiroyuki Gatanaga; Nguyen Vu Trung; Nguyen Van Kinh; Shinichi Oka
Journal:  Glob Health Med       Date:  2020-02-29

4.  Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.

Authors:  J Jao; W Yu; K Patel; T L Miller; B Karalius; M E Geffner; L A DiMeglio; A Mirza; J S Chen; M Silio; E J McFarland; R B Van Dyke; D Jacobson
Journal:  HIV Med       Date:  2017-11-21       Impact factor: 3.180

5.  Virtual support for paediatric HIV treatment decision making.

Authors:  Kirsty Le Doare; N E Mackie; S Kaye; A Bamford; S Walters; C Foster
Journal:  Arch Dis Child       Date:  2014-12-30       Impact factor: 3.791

6.  Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.

Authors:  Pierre Gantner; Firouze Bani-Sadr; Rodolphe Garraffo; Pierre-Marie Roger; Michèle Treger; Thomas Jovelin; Pascal Pugliese; David Rey
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

7.  Serum lipid and glucose profiles in HIV-positive Nigerian children.

Authors:  Olukemi O Ige; Christopher S Yilgwan; Augustine O Ebonyi; Ruth Adah; Idris Adedeji; Esther S Yiltok; Stephen Oguche; Fidelia Bode-Thomas
Journal:  J Virus Erad       Date:  2017-07-01

Review 8.  Darunavir: A Review in Pediatric HIV-1 Infection.

Authors:  Gillian M Keating
Journal:  Paediatr Drugs       Date:  2015-10       Impact factor: 3.930
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.